However, APL blast cells express the CD33 antigen in nearly 100% of APL patients along with a low ABCB1 expression and offer the opportunity of a new treatment option for APL patients [64,65,66]. The gene discussed is ABCB1; the disease is acute promyelocytic leukemia.